Lee et al. [35] explored the effect of the CXCR4 antagonist T22 on the in vivo efficacy of cyclophosphamide in the treatment of established lung metastases from melanoma cells, showing a synergistic drug interaction. The gene discussed is CXCR4; the disease is melanoma.